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Summary The data for this study, consisting of 300 females treated for breast cancer in 1951-1961, were
evaluated in order to ascertain when excess mortality from breast cancer disappears and what would be an
appropriate follow-up period for investigational purposes. The clinical stages of the patients were classified as
follows: 23.3%, stage I; 49%, stage II; 20.3%, stage III and 7.3%, stage IV. Halsted's radical mastectomy was
performed in 79.7% of the cases. Every patient was given radiotherapy. Two hundred and ninety-eight
patients could be followed until death or up to the present. Forty-five patients (16%) were still alive. The
survival rate over a 20-year period for the various stages was as follows: stage I, 46.1%; stage II, 22.7% and
stage III, 10.9%. Only 26% of the patients with stage I died of breast cancer, while the respective figures for
stage II were 57% and stage III, 70%. The death rate from the cancer diminished with time in every stage
especially 10 years after primary treatment. After this the observed survival rate curves were almost parallel
with the expected curves. Our data show that for follow-up studies a 5-year follow-up is good and a 10-year
follow-up is very good to show the trend in the treatment of breast cancer.
There is an increasing awareness among cancer
investigators that breast cancer may be a systemic
disease from its inception (Strax, 1978). There is
also increasing evidence that its initial clinical
manifestation in the vast majority of cases is a
localized lesion in one breast, although there may
be evidence of microscopic totally occult dis-
semination elsewhere (Strax, 1978). That is why a
patient who is still alive five years after the treat-
ment for breast cancer cannot be considered to be
'cured' even if she seems to be disease free. The risk
of dying from breast cancer decreases the longer the
patient survives (Blackwood et al., 1977), and if
breast cancer is detected and treated effectively at a
very early stage there is a 90% probability of
survival over a twenty year period (Frazier et al.,
1977). Because the prognosis for breast cancer
patients is better than for patients suffering from
many other cancers, it is of interest to know when
the excess mortality from breast cancer disappears,
and what a valid follow-up time for breast cancer
patients would be. For this reason a follow-up
study of the breast cancer patients treated in 1951-
1961 in our department was made. Their crude and
age-adjusted twenty year survival rates were
calculated, and causes of death were ascertained.
Material and methods
The original material consisted of 300 female breast
cancer patients treated in 1951-1961 in the Second
Department of Surgery, Helsinki University Central
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Hospital. The 5 year survival rates were published
in 1969 (Peltokallio et al., 1969). The age
distribution of the patients is presented in Figure 1.
The location of the tumour was as frequent in the
right as in the left breast. It was most common in
the upper lateral segment of the mammary gland
(57%). The clinical staging of the disease at the
time of the primary therapy is presented in Table I.
In 79.7% of the cases Halsted's radical mastectomy
was performed. Mastectomy only was performed in
6.3% of the cases and tumour excision in 2%
because of the poor condition of the patients. The
treatment was considered to be palliative on
account of dissemination in 12%. The patients had
postoperative radiotherapy as part of the primary
treatment at that time. The present status of the
patients was ascertained during 1982-1984. Two
hundred and ninety-eight of the 300 patients were
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Figure 1 The age distribution of the patients.
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Table I The clinical stages at the
time of the primary therapy,
1951-1961.
Per cent
N oftotal
Stage 1 70 23.3
Stage II 147 49.1
Stage III 61 20.3
Stage IV 22 7.3
Total 300 100.0
followed until death or up to the present. Forty-
eight patients were alive. The two missing patients
were alive 14 years after the primary therapy but
could not be traced thereafter.
The age-adjusted survival rate was estimated by
the person year procedure method (Breslow & Day,
1982), comparing the death rates to the population
of all Finnish females of the same age in the same
time period (Central Statistical Office of Finland,
1984). The causes of death were verified from the
death certificates.
Results
The patients were divided into different stages by
TNM-classification. The overall survival rate for
the entire material is presented in Figure 2. The
crude mortality rate is compared to the mortality in
the normal Finnish female population of the same
age. The 'corrected' rate (referring only to breast
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Figure 2 The overall survival rate for the whole
material (log scale). I-expected, 2-'corrected', 3-age-
adjusted and 4-crude.
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Figure 3 The crude (x) and 'corrected' (x') survival
rates in different clinical stages (log scale). I-stage I,
II-stage II, III-stage III and IV-stage IV.
cancer mortality, excluding other causes of death)
and the age-adjusted rate for the patients who died
of breast cancer are also given. Seventy-one (24%)
of the patients survived twenty years or more. Only
56% of the 300 females died of breast cancer. The
crude curve and the expected curve show approxi-
mately the same slope starting about 10 years after
the primary treatment, which signifies almost
complete disappearance of excess mortality from
breast cancer. The crude and 'corrected' survival
rates in different clinical stages are presented in
Figure 3. The crude 20 year survival rate in stages
I-III was 46, 23 and 11%, respectively. The age-
adjusted results at 10 years were 65, 45 and 18%,
and at 20 years 71, 36 and 15%, respectively.
However, only 26% of the 70 patients with stage I
disease died of breast cancer. For stage II patients
the respective figure was 57% of the 147 patients,
and for stage III patients, 70% of the 61 patients.
Every patient with stage IV died within 5 years.
Twenty-one of the 22 patients in this group died of
breast cancer. The crude 20 year survival rate in
different T-groups is presented in Figure 4. The
proportion of breast cancer among causes of death
in different groups is presented in Table II. The
death rate for breast cancer diminished with time in
every stage, especially after 10 years following
primary treatment. It was lowest in stage I after 10
years (X2=P<0.01), but even then 33% of the
causes of death were attributable to breast cancer.
Discussion
Twenty year survival studies on breast cancer are
rare. Because Finland is a small country, it was
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Table II The proportion of breast cancer among causes of death in
different stages in two 10-year periods after the primary treatment.
0-10 years 10-20 years
Breast cancer Total Breast cancer Total
Patients deaths deaths deaths deaths
(N) (N) (N) (N) (N)
Stage I 70 15 29 2 6
Stage II 147 75 93 10 23
Stage III 61 43 54 2 3
Stage IV 22 21 22
Total 300 154 198 14 32
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Figure 4 The crude survival rate in different T-groups
(log scale). I-TI under 2cm, 2-T2 2-5cm and 3-T3-4
over 5cm or a tumour with skin or chest wall
infiltration.
possible to locate patients even after 20-30 years,
and to clarify their present status. This kind of
retrospective study is made reliable by the fact that
a physician prepares a death certificate, complete
with diagnosis of causes of death, for every
deceased person.
Estimating the prognosis for breast cancer
patients following different treatments is not
possible within the scope of the present study
because most of our patients underwent Halsted's
radical mastectomy, and radiotherapy was given as
part of the primary treatment. A recent randomized
clinical trial of 1665 women, comparing radical
mastectomy and total mastectomy with or without
radiation, gave no indications of a significant
difference between the different treatment groups
(Fisher et al., 1985). The ten year survival rate
estimated by the actuarial life-table method was
57% for the patients with MO and clinically
negative axillary nodes, and 38% for those with
clinically positive nodes. The corresponding crude
results in our material were 55 and 38%, respec-
tively. It therefore seems that the choice between
local and radical treatment is not of importance
with respect to the survival of patients with breast
cancer. However, the present trend in the treatment
of breast cancer in Finland is more conservative.
According to our study, the size of the tumour
had a significant effect on the prognosis, especially
according to the long term follow-up. (With TI the
twenty year survival rate was 37%, with T2, 24%
and with T3-4, 17%; P<0.001). However, it has
been shown that it is not sufficient to estimate the
prognosis purely on the basis of the size of the
tumour, especially in the case of small cancers
(Bedwani et al., 1981). The status of axillary nodes
may determine whether or not a small invasive
tumour less than one centimeter in diameter may be
considered a minimal cancer.
The long term prognosis for breast cancer
patients is especially dependant on the clinical stage
of the disease at the time of the primary diagnosis.
In this study the crude ten year survival rate in
stages I-IV was 55, 38, 16 and 0%, respectively. In
several studies involving modified or radical
mastectomy with or without postoperative radio-
therapy the corresponding results were on the same
level (Leis, 1979; Muir & White; 1967, Nikkanen et
al., 1981; Schottenfeld et al., 1976).
Excess mortality from breast cancer continues
twenty years after the primary treatment, although
its proportion among deaths decreases with time
(Hakulinen et al., 1982). In a long-term study in the
Cambridge area (UK) it has been shown that even
after 20 years follow-up there are 16 times more
deaths from breast cancer than expected in the
normal population, although the overall death rates
in the two groups were the same (Brinkley &
Haybittle, 1975). The trend was also confirmed on
the basis of our material. The excess mortality from
breast cancer decreased especially after ten years,
when the survival curves almost paralleled the
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expected curves. A study of the hazard function or
force of mortality from breast cancer revealed that
the risk of dying of the cancer decreased the longer
a patient survived (Blackwood et al., 1977). This
information is important. Our data show that for
follow-up studies, a five year follow-up is good, and
a ten year follow-up is very good for showing the
trend in the treatment of breast cancer.
However, it is emphasized that patients with
breast cancer must be followed up even after the
ten year period referred to above because there is a
four- to five-fold increased risk of contralateral
breast cancer (Schoenberg, 1977; Schottenfeld &
Berg, 1975) or recurrence. This would maximize the
chance of cure and, when necessary, optimize
palliation (Horton, 1984).
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